Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Evusheld
Evusheld is a combination of two monoclonal antibodies, tixagevimab and cilgavimab, designed to provide pre-exposure prophylaxis (PrEP) against SARS-CoV-2 infection. It is administered intramuscularly and is intended for individuals who are moderately to severely immunocompromised and may not mount an adequate immune response to COVID-19 vaccination or for individuals for whom vaccination is not recommended. Evusheld is not a treatment for COVID-19 and is not authorized for use in individuals who have been exposed to or infected with SARS-CoV-2.
Evusheld is used for pre-exposure prophylaxis of COVID-19 in certain immunocompromised individuals.
Outcome:
Reduced vaccine efficacy
Mechanism:
Neutralization of vaccine virus
Outcome:
Reduced efficacy of either drug
Mechanism:
Potential interaction with immune response
Outcome:
Reduced absorption of Evusheld
Mechanism:
Chelation or altered pH
Next-generation monoclonal antibody cocktails with broader variant coverage are expected to emerge by 2024 (70% confidence).
Due to reduced effectiveness against emerging variants, Evusheld is unlikely to regain FDA approval in its current formulation.
Monoclonal Antibody Combination
Immunoglobulin G (IgG)